TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00005798

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)

Intervention type: DRUG
Group type: OTHER
Intervention: Thiotepa
Description: Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
Study: NCT01376778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMV hyperimmune globulin
Description: The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
Study: NCT01023633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, LV, 5-FU
Description: Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, LV, 5-FU
Description: Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W
Study: NCT02295345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia
Study: NCT00894062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)
Description: Zotarolimus eluting stent (ZES)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent (Xience - EES)
Description: Everolimus eluting stent (EES)
Study: NCT01089348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactofiltrum + Metronidazole
Description: Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500 mg 1 tablet BID for 7 days per os
Study: NCT03533647

Intervention type: OTHER
Intervention: Observational
Description: none (observational study)
Study: NCT02310776

Intervention type: DEVICE
Group type: OTHER
Intervention: Supine automated breast ultrasound scanner
Description: Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.

Intervention type: DEVICE
Group type: OTHER
Intervention: High-resolution handheld breast ultrasound
Description: Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
Study: NCT03007368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice
Description: Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potato
Description: Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasta
Description: Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorghum thick porridge
Description: Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Millet thick porridge
Description: Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Millet couscous
Description: Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Millet thin porridge
Description: Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Millet thin monikuru porridge
Description: Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
Study: NCT01709084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
Study: NCT01605279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
Study: NCT02363348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L arginine
Description: L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calcined magnesia
Study: NCT04416555

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: VR googles and the non reality experience
Description: parallel assignment (this arm will receive a static presentation in the same device)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: VR googles and the real VR program to enter act with and experience
Description: Parallel assignment (this arm will receive the full immersive virtual reality experience
Study: NCT01568775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: All patient and subjects received single dose of aliskiren 300 mg in treatment period.
Study: NCT00737191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT04134182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg intravenously every 2 weeks during 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg intravenously every 3 weeks for four doses
Study: NCT02017353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcuphyt
Study: NCT01948336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
Study: NCT05063721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesoangioblasts
Description: intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)
Study: NCT00721370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR imaging system
Description: Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
Study: NCT04344470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG
Description: EMG will be recorded from two electrodes placed on both extensor carpi radialis (ECR) muscles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG electrodes will be positioned according to 10-20 International System, with every impedance kept under 5 kOhm. EEG data will be amplified, filtered (DC-100 Hz), digitized at 1000 Hz, and stored on a computer for offline analysis.
Study: NCT04565886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser application
Description: After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Adjunctive diode laser (settings: 810 nm, 2.5 W, 50 Hz, 10 ms) will be applied 3x for 30 s (i.e., 90 s per appointment) using a 400-lm thick fiber (WhiteStar, Orcos Medical AG, Küsnacht, Switzerland) in the test group. In the control group, non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way. The laser tip will be checked after 4-5 s for coagulation to prevent hotspots in the soft tissues.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Diode laser
Description: After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way.
Study: NCT01104038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXCEL
Description: Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXCEL
Description: Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education ONLY
Description: Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
Study: NCT00143663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat Acetate
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
Study: NCT03680911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetyl Cysteine
Description: 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
Study: NCT01699477

Intervention type: DEVICE
Group type: OTHER
Intervention: ExAblate 4000 focused ultrasound brain intervention
Description: Non-invasive brain intervention using MR-guided focused ultrasound
Study: NCT03532594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRODOSE Algorithm
Description: Protamine administered according to PRODOSE algorithm

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Care
Description: Protamine administered according to Standard Care
Study: NCT03428763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Homebased disease monitoring (eHealth)
Description: Participants allocated to the intervention group will be trained in self-monitoring (assessment of tender of swollen joints). Further they will be instructed in using a point-of-care CRP-measuring device to measure blood concentrations of C-reactive protein at their home, and to submit the self-monitoring results on a dedicated internet platform. These procedures represent a virtual visit.~The participants are instructed to have virtual visit (self-monitoring) every month from allocation. The scheduled virtual visits include~* Joint score by the patient~* Patient global disease activity measured on a 0-100 mm visual analogue scale.~* CRP measurement on home-based device Based on the submitted data a DAS28-CRP is calculated and recorded in the eCRF.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical disease monitoring
Description: Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
Study: NCT04428021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Therapy Protocol (STP)
Description: Standard Therapy Protocol according to the best evidence treatment recommended by the Regional Health System emergency committee

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Therapy Protocol (STP)
Description: Standard Therapy Protocol according to the best evidence treatment recommended by the Regional Health System emergency committee

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy Protocol (STP)
Description: Standard Therapy Protocol according to the best evidence treatment recommended by the Regional Health System emergency committee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STP + Standard Plasma (SP)
Description: Transfusion of three Standard Plasma Units (SP) on day 1,3,5 in addition to STP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STP + COVID-19 Convalescent Plasma (CP)
Description: Transfusion of three SARS-Cov-2 neutralizing antibodies positive Plasma Units (CP) on day 1,3,5 in addition to STP
Study: NCT01903707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
Study: NCT04252053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Based Core Stabilization Training
Description: Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise
Description: Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
Study: NCT03147781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True AT with magnetic pellets
Description: Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham AT with Medulla Junci
Description: Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
Study: NCT00631020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBME
Description: 6 weeks of once a week one-on-one CBME

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional NRT
Description: NicoDerm CQ nicotine transdermal patch
Study: NCT03220542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Saccharomyces boulardii

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli
Description: Broccoli sprouts extract

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin
Study: NCT03279614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
Study: NCT00507390

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 polyunsaturated fatty acids (PUFAs)
Description: 2g n-3 PUFAs once daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: 1 capsule day
Study: NCT03221751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prazosin hydrochloride
Description: Prazosin is an oral capsule. It is an alpha-1 antagonists.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is an inert oral capsule identical in appearance to prazosin capsules.
Study: NCT03986385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Capecitabine Oxaliplatin
Description: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Oxaliplatin
Description: Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
Study: NCT00131469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide (FORTEO)
Description: Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT01063075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - FU
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - FU
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - FU
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - FU
Description: Administered Intravenously
Study: NCT04868721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations
Description: three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations
Description: three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
Study: NCT02769663

Intervention type: BEHAVIORAL
Intervention: questionnaires and neuropsychological assessments

Intervention type: BEHAVIORAL
Intervention: questionnaires and neuropsychological assessments